- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02627053
Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
November 24, 2018 updated by: Walter Ageno, Università degli Studi dell'Insubria
Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients.
Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis.
The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
Patients with splanchnic vein thrombosis are at increased risk of recurrent VTE and bleeding.
Routine anticoagulation with unfractionated heparin or low molecular weight heparin followed by warfarin is recommended in this setting, but limited data is available to support this recommendation and more than 20% of these patients do not receive antithrombotic treatment due the fear for bleeding complications.
The pharmacokinetic and pharmacodynamic characteristics of rivaroxaban make this drug an ideal alternative therapeutic strategy for the treatment of patients with SVT.
Thanks to the oral route of administration, the short half-life, the high bioavailability, the predictable dose-response and the lack of effects on platelet activity, rivaroxaban could result as an important alternative to both LMWH and warfarin in the acute and long-term treatment of SVT patients.
Furthermore, the analysis of phase III studies conducted in patients with DVT or PE have shown a better safety profile of rivaroxaban as compared to standard of treatment.
This observed benefit in the safety profile of rivaroxaban would be extremely relevant in the treatment of patients with SVT.
In this prospective cohort study, patients presenting with acute SVT will receive rivaroxaban 15 mg bid for 3 weeks followed by rivaroxaban 20 mg od for a total of 3 months.
The primary safety and efficacy outcomes will be measured at 3 months.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamilton, Canada
- Recruiting
- McMaster University
-
Contact:
- Mark Crowther, MD
-
London, Canada
- Recruiting
- University of Western Ontario
-
Contact:
- Alejandro Lazo-Langner, MD
-
Ottawa, Canada
- Recruiting
- University of Ottawa
-
Contact:
- Marc Carrier, MD
-
Principal Investigator:
- Aurelien Delluc
-
-
-
-
-
Varese, Italy, 21100
- Recruiting
- Ospedale di Circolo
-
Contact:
- Giovanna Colombo
- Email: givacolo@hotmail.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 96 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Consecutive patients aged 18 years or older
- first episode of symptomatic, objectively diagnosed PVT, MVT, or spVT
- signed informed consent.
Exclusion criteria:
- known liver cirrhosis (biopsy proven or with clinical, laboratory, or imaging evidence of chronic liver disease, within a context of chronic alcoholism, viral hepatitis, autoimmunity, Wilson's disease, iron overload)
- alanine aminotransferase level that is three times the upper limit of the normal range or higher
- Budd-Chiari syndrome
- previous or ongoing vatical bleeding
- presence of portal vein cavernoma at the time of diagnosis
- anticipated abdominal surgical procedure
- known bleeding diathesis
- platelet count <100.000 mm3
- creatinine clearance <30 mL/min (Cockroft-Gault formula)
- life expectancy of less than 3 months
- expected inability to take oral medications
- concomitant treatment with azole antimycotics and human immunodeficiency virus protease inhibitors - treatment with therapeutic doses of LMWH or UFH for more than 7 days
- ongoing treatment with VKA
- pregnancy or lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: rivaroxaban
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Major bleeding
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
June 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
December 7, 2015
First Submitted That Met QC Criteria
December 9, 2015
First Posted (Estimate)
December 10, 2015
Study Record Updates
Last Update Posted (Actual)
November 27, 2018
Last Update Submitted That Met QC Criteria
November 24, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIVASVT-100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.